Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287420 | 0.80 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL2080260 | 0.77 | CYP1A2 (0.46) | ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL2866244 | 0.77 | HDAC1 (0.71) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL3436257 | 0.77 | ALDH1A1 (0.56) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL27700829 | 0.76 | ALDH1A1 (0.54) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL7744184 | 0.76 | HDAC1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL2560216 | 0.76 | HDAC1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL16898659 | 0.74 | ALDH1A1 (0.45) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL3436258 | 0.74 | ALDH1A1 (0.47) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL2870864 | 0.73 | HDAC1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101426774-B | Azolecarboxamide derivative | ASTELLAS PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-101426774-A | Azolecarboxamide derivative | ASTELLAS PHARMA INC (JP) | 2009-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALDH1A1 975/4885HDAC1 372/4885HDAC8 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.